Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
linvoseltamab + fianlimab
- Development stage
- Phase 1
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
linvoseltamab + fianlimab is an investigational combination therapy that includes linvoseltamab, a bispecific antibody targeting B-cell maturation antigen (BCMA), and fianlimab, an anti-LAG-3 (lymphocyte activation gene-3) human monoclonal antibody. Linvoseltamab is in development primarily as a T-cell engager for multiple myeloma. Fianlimab is in development as an immune checkpoint inhibitor. The combination is being studied in clinical trials for patients with relapsed or refractory multiple myeloma to assess safety, tolerability, pharmacokinetics, and antitumor activity, with the goal of improving responses through complementary immune-mediated mechanisms[3]. Both drugs are being developed by Regeneron.
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)LAG3 (Lymphocyte activation Gene-3 protein)
Beyond the preview
Go deeper on linvoseltamab + fianlimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on linvoseltamab + fianlimab.